Cargando…

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CL protease (3CL(pro)) has been regarded as an extremely promising antiviral target for the treatment of coronavirus disease 2019 (COVID-19). Here, we carried out a virtual screening based on commercial compounds database to find nove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Muya, Nie, Tianqing, Shao, Qiang, Li, Minjun, Su, Haixia, Xu, Yechun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783839/ https://www.ncbi.nlm.nih.gov/pubmed/35114541 http://dx.doi.org/10.1016/j.ejmech.2022.114130

Ejemplares similares

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
por: Wang, Qian, et al.
Publicado: (2023)

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
por: Su, Haixia, et al.
Publicado: (2021)

Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches
por: Shao, Qiang, et al.
Publicado: (2023)

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety
por: Zhu, Mengwei, et al.
Publicado: (2023)

Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen
por: Wang, Liying, et al.
Publicado: (2022)

Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2
por: Ren, Pengxuan, et al.
Publicado: (2023)

Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
por: Jiang, Xiangrui, et al.
Publicado: (2023)

Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study
por: Shen, Jian-Xin, et al.
Publicado: (2023)

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking
por: Vázquez-Mendoza, Luis Heriberto, et al.
Publicado: (2022)

In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
por: Wen, Lei, et al.
Publicado: (2021)

In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease
por: Gao, Menghan, et al.
Publicado: (2023)

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
por: Liu, Yu-Chih, et al.
Publicado: (2005)

Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
por: Ge, Rui, et al.
Publicado: (2022)

Drug discovery and development targeting the life cycle of SARS-CoV-2
por: Su, Haixia, et al.
Publicado: (2021)

Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method
por: Zhu, Dafu, et al.
Publicado: (2022)

In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database
por: Muhtar, Eldar, et al.
Publicado: (2021)

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease
por: Zeyaullah, Md., et al.
Publicado: (2023)

Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
por: Zhang, Ya-Ni, et al.
Publicado: (2023)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Non-covalent SARS-CoV-2 M(pro) inhibitors developed from in silico screen hits
por: Rossetti, Giacomo G., et al.
Publicado: (2022)

Boroleucine‐Derived Covalent Inhibitors of the ZIKV Protease
por: Braun, Niklas J., et al.
Publicado: (2022)

Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
por: Li, Qizhang, et al.
Publicado: (2020)

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
por: Shang, Weijuan, et al.
Publicado: (2022)

Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
por: Scarpino, Andrea, et al.
Publicado: (2019)

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors
por: Ibrahim, Mahmoud A.A., et al.
Publicado: (2020)

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
por: Farhat, Ameny, et al.
Publicado: (2022)

Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL(pro): Inhibition potentials, covalent binding sites and inhibitory mechanisms
por: Xiong, Yuan, et al.
Publicado: (2021)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Chetomin, a SARS-CoV-2 3C-like Protease (3CL(pro)) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2023)

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
por: Shao, Yi-Ming, et al.
Publicado: (2008)

Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL(Pro)) of SARS-CoV-2: in silico study
por: Mathpal, Shalini, et al.
Publicado: (2022)

Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study
por: Ibrahim, Mahmoud A.A., et al.
Publicado: (2021)

In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2023)

CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
por: Du, Hongyan, et al.
Publicado: (2020)

Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
por: Krüger, Nadine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v6ft2h25ar7n55ggv51bq5g0om